Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth C Anderson

Showing results (241-250 of 868) with videos related to

Pageof 87
Sort By:
Cancers|June 11, 2020
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple MyelomaShih-Feng Cho, Liang Lin, Lijie Xing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2011
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cellsDharminder Chauhan, Ze Tian, Bin Zhou, et al.
Seminars in Oncology|October 19, 2013
Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targetsPanisinee Lawasut, Richard W J Groen, Eugen Dhimolea, et al.
Expert Opinion on Pharmacotherapy|November 28, 2017
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and againstPaul G Richardson, Sarah A Holstein, Robert L Schlossman, et al.
Leukemia|April 3, 2020
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathwaysTeru Hideshima, Daisuke Ogiya, Jiye Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2005
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myelomaTeru Hideshima, James E Bradner, Jason Wong, et al.
Blood|April 2, 2011
A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cellsAjita V Singh, Madhavi Bandi, Noopur Raje, et al.
Antibodies (Basel, Switzerland)|September 25, 2019
Monoclonal Antibody: A New Treatment Strategy against Multiple MyelomaShih-Feng Cho, Liang Lin, Lijie Xing, et al.
Leukemia Research|October 29, 2008
The current landscape of multiple myeloma treatmentMichele Cavo, Michel Attal, Morie A Gertz, et al.
Blood Cancer Journal|December 10, 2023
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myelomaDebasmita Dutta, Jiye Liu, Kenneth Wen, et al.
Pageof 87

Showing results (241-250 of 868) with videos related to

Sort By:
Pageof 87
Cancers|June 11, 2020
BCMA-Targeting Therapy: Driving a New Era of Immunotherapy in Multiple MyelomaShih-Feng Cho, Liang Lin, Lijie Xing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2011
In vitro and in vivo selective antitumor activity of a novel orally bioavailable proteasome inhibitor MLN9708 against multiple myeloma cellsDharminder Chauhan, Ze Tian, Bin Zhou, et al.
Seminars in Oncology|October 19, 2013
Decoding the pathophysiology and the genetics of multiple myeloma to identify new therapeutic targetsPanisinee Lawasut, Richard W J Groen, Eugen Dhimolea, et al.
Expert Opinion on Pharmacotherapy|November 28, 2017
Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and againstPaul G Richardson, Sarah A Holstein, Robert L Schlossman, et al.
Leukemia|April 3, 2020
Immunomodulatory drugs activate NK cells via both Zap-70 and cereblon-dependent pathwaysTeru Hideshima, Daisuke Ogiya, Jiye Liu, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 7, 2005
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myelomaTeru Hideshima, James E Bradner, Jason Wong, et al.
Blood|April 2, 2011
A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cellsAjita V Singh, Madhavi Bandi, Noopur Raje, et al.
Antibodies (Basel, Switzerland)|September 25, 2019
Monoclonal Antibody: A New Treatment Strategy against Multiple MyelomaShih-Feng Cho, Liang Lin, Lijie Xing, et al.
Leukemia Research|October 29, 2008
The current landscape of multiple myeloma treatmentMichele Cavo, Michel Attal, Morie A Gertz, et al.
Blood Cancer Journal|December 10, 2023
BCMA-targeted bortezomib nanotherapy improves therapeutic efficacy, overcomes resistance, and modulates the immune microenvironment in multiple myelomaDebasmita Dutta, Jiye Liu, Kenneth Wen, et al.
Pageof 87